Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force
暂无分享,去创建一个
[1] Mark W. Dewhirst,et al. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response , 2008, Nature Reviews Cancer.
[2] Robert S. Kerbel,et al. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.
[3] R. Boidot,et al. Identification of Cyclooxygenase-2 as a Major Actor of the Transcriptomic Adaptation of Endothelial and Tumor Cells to Cyclic Hypoxia: Effect on Angiogenesis and Metastases , 2010, Clinical Cancer Research.
[4] M. Dewhirst,et al. Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis , 2012, PloS one.
[5] C. Thompson,et al. Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.
[6] Julien Verrax,et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.
[7] Bruce Klitzman,et al. Direct demonstration of instabilities in oxygen concentrations within the extravascular compartment of an experimental tumor. , 2006, Cancer research.
[8] Franziska Hirschhaeuser,et al. Lactate: a metabolic key player in cancer. , 2011, Cancer research.
[9] J. Nielsen,et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Curi,et al. Maximum activities of some key enzymes of glycolysis, glutaminolysis, Krebs cycle and fatty acid utilization in bovine pulmonary endothelial cells , 1987, FEBS letters.
[11] Shankar C. Sanka,et al. Vacuolar-type H+-ATPases at the plasma membrane regulate pH and cell migration in microvascular endothelial cells. , 2006, American journal of physiology. Heart and circulatory physiology.
[12] M. V. Heiden,et al. Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.
[13] V. Grégoire,et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. , 2006, Cancer research.
[14] S. Richard,et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia , 2012, Haematologica.
[15] B. Reglin,et al. Structural response of microcirculatory networks to changes in demand: information transfer by shear stress. , 2003, American journal of physiology. Heart and circulatory physiology.
[16] C. Dalgard,et al. Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1* , 2005, Journal of Biological Chemistry.
[17] J. Esplugues,et al. Regulation of Oxygen Distribution in Tissues by Endothelial Nitric Oxide , 2009, Circulation research.
[18] T. Copetti,et al. Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review , 2011, Front. Pharmacol..
[19] Holger Gerhardt,et al. Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.
[20] K. Bennewith,et al. Quantifying Transient Hypoxia in Human Tumor Xenografts by Flow Cytometry , 2004, Cancer Research.
[21] S. Weinhouse. On respiratory impairment in cancer cells. , 1956, Science.
[22] Frederik De Smet,et al. Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization , 2009, Cell.
[23] J. Nielsen,et al. Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity , 2006, Proceedings of the National Academy of Sciences.
[24] W. Zwerschke,et al. Premature senescence of human endothelial cells induced by inhibition of glutaminase , 2008, Biogerontology.
[25] E. Rofstad,et al. Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis , 2007, Clinical Cancer Research.
[26] S. Bonhoeffer,et al. Cooperation and Competition in the Evolution of ATP-Producing Pathways , 2001, Science.
[27] M. Dewhirst,et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. , 1996, Cancer research.
[28] Richard P. Hill,et al. Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.
[29] C. Dessy,et al. Vascular Hypoxic Preconditioning Relies on TRPV4-Dependent Calcium Influx and Proper Intercellular Gap Junctions Communication , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[30] V. Grégoire,et al. Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery , 2006, Molecular Cancer Therapeutics.
[31] O. Féron. Challenges in Pharmacology of Anti-Cancer Drugs – The Search for Addictions , 2010, Front. Pharm..
[32] G. Breier,et al. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ. , 2011, Cancer research.
[33] Peter Carmeliet,et al. Regulation of angiogenesis by oxygen and metabolism. , 2009, Developmental cell.
[34] James B. Mitchell,et al. Imaging cycling tumor hypoxia. , 2010, Cancer research.
[35] A. Giaccia,et al. PHD2 in tumour angiogenesis , 2010, British Journal of Cancer.
[36] Benoit Macq,et al. Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? , 2004, Physics in medicine and biology.
[37] O. Feron,et al. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments , 2011, Disease Models & Mechanisms.
[38] O. Feron,et al. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[39] O. Barbash,et al. Expression of Angiogenic Factors Vascular Endothelial Growth Factor and Interleukin-8/CXCL8 Is Highly Responsive to Ambient Glutamine Availability , 2004, Cancer Research.
[40] Tim Crook,et al. The prolyl‐hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia , 2010, European journal of haematology.
[41] Richard P. Hill,et al. Acute Hypoxia Enhances Spontaneous Lymph Node Metastasis in an Orthotopic Murine Model of Human Cervical Carcinoma , 2004, Cancer Research.
[42] C. Dessy,et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. , 2012, Cancer research.
[43] Pierre Sonveaux,et al. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. , 2011, Cancer research.
[44] D. Yellon,et al. The therapeutic potential of ischemic conditioning: an update , 2011, Nature Reviews Cardiology.
[45] William C. Aird,et al. Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms , 2007, Circulation research.
[46] Howard Y. Chang,et al. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. , 2009, Cancer cell.
[47] B. Gallez,et al. Nitric oxide delivery to cancer: why and how? , 2009, European journal of cancer.
[48] E. Rofstad,et al. Fluctuations in tumor blood perfusion assessed by dynamic contrast‐enhanced MRI , 2007, Magnetic resonance in medicine.
[49] J. Balligand,et al. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. , 2009, Physiological reviews.